| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10175666 | Journal of Orthopaedic Science | 2010 | 7 Pages |
Abstract
Our results did not indicate effectiveness of imatinib monotherapy at a dose of 600 or 800 mg/day in patients with relapsed or refractory KIT-positive (excluding GISTs) or PDGFR-positive sarcomas. Our findings suggest the need to evaluate the synergistic effect of combination therapy with other anticancer drugs.
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
Hideshi Sugiura, Yasuhiro Fujiwara, Masashi Ando, Akira Kawai, Akira Ogose, Toshifumi Ozaki, Ryohei Yokoyama, Toru Hiruma, Takeshi Ishii, Hideo Morioka, Hideo Mugishima,